论文部分内容阅读
Epigenetic-modulating agents can concurrently target multiple aberrant or compensatory signaling pathways found in cancer cells.However, existing epigenetic-modulating agents in cancer treatment have not yet fully translated into survival benefits beyond hematological tumors.